Quantumzyme Corp. will participate in the Catalysis and Chemical Engineering Conference (CCE-2026) in Boston from March 9-11, 2026, where the company will present advancements in sustainable enzyme engineering that are transforming pharmaceutical manufacturing. The company's technology addresses critical environmental challenges in chemical synthesis while improving production efficiency and supporting domestic manufacturing capabilities.
The company's enzyme engineering platform enables sustainable, cost-efficient pathways for pharmaceutical manufacturing, aligning with growing global demand for low-waste, energy-efficient production methods. Quantumzyme will highlight specific developments in green ibuprofen synthesis, featuring biocatalytic routes that significantly reduce environmental impact and manufacturing costs compared to traditional chemical processes.
These innovations demonstrate practical, scalable solutions that support cleaner pharmaceutical production while addressing key industry challenges. Current Active Pharmaceutical Ingredients (API) production often relies on legacy chemistries that generate substantial waste and require high solvent usage. Quantumzyme's platform aims to transform this landscape by reducing waste and solvent consumption, lowering carbon intensity in API production, improving process reliability and consistency, and supporting U.S. onshoring and supply-chain resilience for essential medicines.
The company is expanding its enzyme engineering platform to high-volume APIs, including new applications in chiral molecule synthesis supported by next-generation ketoreductase (KRED) enzymes. This expansion represents significant progress for pharmaceutical and fine-chemical markets where precise molecular synthesis is crucial. The technology's alignment with global sustainability and decarbonization goals positions Quantumzyme as a key contributor to the broader transformation of pharmaceutical manufacturing toward environmentally responsible production.
Throughout CCE-2026, Quantumzyme plans to engage with researchers, academic collaborators, pharmaceutical manufacturers, process development teams, technology developers, and investors focused on green chemistry and biomanufacturing. These discussions are intended to explore partnerships that may accelerate the adoption of enzyme-based manufacturing approaches across high-volume API production. The company's participation reflects its continued commitment to advancing next-generation biocatalysis and driving innovation across pharmaceutical and specialty chemicals industries.
For additional information, visit https://www.quantumzymecorp.com and the company's profile at https://www.otcmarkets.com/stock/QTZM. The company's CEO Naveen Kulkarni stated that CCE-2026 provides an excellent platform to share their vision for sustainable chemical manufacturing and demonstrate how enzyme engineering technology may offer practical pathways toward cleaner and more efficient production.
